Biosense Webster (israel), Ltd. CARTO 3 System (Software Version V7.1.80), CARTO VISITAG Module - Product Usage: FGThe intended use of the system is catheter-based cardiac electrophysiological (EP) procedures. The system provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure, Product Number: -5400-00, UDI: 10846835000870 Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
CARTO 3 System (Software Version V7.1.80), CARTO VISITAG Module - Product Usage: FGThe intended use of the system is catheter-based cardiac electrophysiological (EP) procedures. The system provides information about the electrical activity of the heart and about catheter location during the procedure. The system can be used on patients who are eligible for a conventional electrophysiological procedure, Product Number: -5400-00, UDI: 10846835000870
Brand
Biosense Webster (israel), Ltd.
Lot Codes / Batch Numbers
All serial numbers
Products Sold
All serial numbers
Biosense Webster (israel), Ltd. is recalling CARTO 3 System (Software Version V7.1.80), CARTO VISITAG Module - Product Usage: FGThe intended use due to Software defect may result in disapperance of tag sites during recalculation and lead to additional ablation sites. This may lead to prolongation of t. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Software defect may result in disapperance of tag sites during recalculation and lead to additional ablation sites. This may lead to prolongation of the procedure and, in extremely rare circumstances, cardiac perforation.
Recommended Action
Per FDA guidance
On 06/22/2020, the firm notified affected US customers via mail of a hospital letter, "URGENT Medical Device Correction", which indicates the following: This product is not being removed from the market and does not need to be returned. A software service pack will be provided by the firm. Your representative will notify you when it is available and will arrange for installation of the service pack. In the meantime, the firm has identified certain mitigations preventing the issue from occurring: If your system is equipped with the VISITAG SURPOINT Module License: - Always enable the VISITAG SURPOINT Module and ensure that the External Processing Unit (EPU) is connected before starting a case. - When using review mode, ensure that the EPU is connected before entering the study and verify that a green connection indication is present on the screen. - When CARTO VISITAG recalculation was performed without the VISITAG SURPOINT Module enabled, recalculate the CARTO VISITAG results with the VISITAG SURPOINT Module by physically reconnecting the EPU, then exit and continue the study and verify that a green connection indication is present on the screen. If your system is not equipped with a VISITAG SURPOINT Module License: - Avoid triggering CARTO VISITAG recalculations as much as possible. - During the procedure consider applying a manual tag for each ablation location by acquiring an ablation point in addition to the CARTO VISITAG Module marking the ablation locations. - If a CARTO VISITAG tag disappears, the CARTO 3 system will still provide an indication of ablation at this location for the manually acquired points. - During offline review of a previous study, be aware that some CARTO VISITAG tags may have disappeared. For next steps, 1. Please review this letter carefully and share it with anyone in your facility that needs to be informed. 2. Please complete, sign, and return the Business Reply Form to the fim via email. The firm notif
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026